Intomics and the global pharmaceutical company H. Lundbeck has signed an agreement which will intensify the ongoing collaboration between the two companies. This underpins the massive inherent value which the Intomics solution can provide to the pharmaceutical industry.

The agreement gives H. Lundbeck access to the advanced data mining services provided by Intomics A/S with the aim to accelerate discovery projects. Lundbeck gains access to Intomics' expertise within bioinformatics and systems biology and Intomics will assist Lundbeck with methods and tools for analyzing and integrating large quantities of biological data generated in the drug development process.

"Lundbeck has some exciting projects and we look forward to assist in making these even more successful. We believe that we can make a difference for Lundbeck by helping with the analysis of the large quantities of data that they generate in the process of drug development and translational research. With our data analysis capabilities and Lundbeck's expertise in the central nervous system area, we see a great synergy that has the potential to benefit patients with CNS related disorders", says Thomas S. Jensen, CEO of Intomics.